When does Dupixent lose exclusivity in Japan?
Dupixent (dupilumab) has had product- and patent-related exclusivity protections in Japan, but the exact “loss of exclusivity” date depends on which form of exclusivity you mean (patents vs. regulatory data/exclusivity tied to marketing authorization). The provided information does not include the relevant Japan patent or regulatory exclusivity timelines, so a precise date can’t be stated here.
What counts as “loss of exclusivity” for Dupixent in Japan?
In Japan, companies and analysts often mean one (or more) of these when they say exclusivity ends:
- Patent expiry (including primary and potentially later-filed “second-generation” patents, if they exist)
- Regulatory data exclusivity tied to the original marketing authorization
- Any additional market protections that delay approval/launch of competitors even before all patents expire
Without the specific patent numbers or the marketing-authorization exclusivity facts for Japan, the endpoint date cannot be confirmed.
What could happen in Japan once exclusivity ends?
Once Japan’s relevant exclusivity barriers end, biosimilar and/or other follow-on manufacturers can potentially pursue:
- Approval pathways for biosimilar entry (timing still depends on the regulatory route and whether any remaining patents cover the product)
- Launch of an approved biosimilar only after any remaining patent “stay” or infringement-avoidance position is resolved
So “exclusivity ends” doesn’t automatically guarantee “instant generic-equivalent launch,” but it removes one of the key legal/clinical barriers to entry.
Are there likely competitors entering Japan around that time?
If Japan’s relevant protections for Dupixent end, the most likely entrants would be biosimilar versions of dupilumab. However, which companies can launch in practice depends on:
- Whether any patents remain in force
- Whether Japan-specific regulatory approvals have already been granted or are pending
- Litigation outcomes or settlement agreements (if any)
What I need to give you the exact Japan date
If you share any of the following, I can pinpoint the “loss of exclusivity” timeline more precisely:
- The specific exclusivity type you mean (patent expiry vs. regulatory data exclusivity)
- The Japan patent numbers (or a link to the listing you’re using)
- The target year/date you’ve seen mentioned and where it came from (report, label, database)
Sources
No sources were provided with your question, so I can’t cite or verify a specific Japan exclusivity-loss date for Dupixent.